Abstract
Overview
Introduction
Antibody-based agents represent a novel approach to the treatment and
prophylaxis of infectious diseases. In recent years, considerable interest has
been expressed in their further development, driven by advances in technology
that improve manufacturing cost and tolerability: fully human antibody
reagents avoid the toxicities associated with traditional human- or
animal-derived serum therapy.
Scope
- An overview of the past, current and emerging technologies for biologics
as well as obstacles faced in development
- Discussion of antibody products in development for several viral
infections and their probable use
- An assessment of pipeline antibody agents targeting important bacterial
and fungal nosocomial pathogens
- A review of the key unmet needs within bacterial, viral and fungal
infections along with an outline of the commercial outlook for antibody agents
Report Highlights
Antibodies offer several advantages over conventional anti-infectives and
vaccines but their cost and mode of administration limits their use in certain
areas.A high unmet need and defined target groups are required to gain
commercial success.Pipeline products fulfilling these criteria have a greater
chance of commercial and scientific success.
Accounting for the majority of nosocomial infections, MRSA is the most popular
target for antibody development. Despite concerns over resistance there are
still several antibiotics that can treat multi-drug resistant S.aureus,
reducing the need for antibody-based therapeutics. The greater need lies in
treatment of Pseudomonas and fungal infections.
For most viral infections, conventional therapies are able to control disease
progression effectively. In HIV and HCV the real need is for a cure or
preventative measure but the majority of pipeline products are being developed
for treatment of these infections.
Reasons to Purchase
- Identify the key antibody products in development for bacterial, viral and
fungal infections
- Examine the remaining and emerging unmet needs in the infectious diseases
market and identify opportunities for antibody product development
- Gain an overview of the commercial outlook for antibody based products and
their likely positioning in the prophylaxis and treatment of infections
| 
View Cart
